A people’s misfortunes among people have benefits, a saying that actually applies to global pharmaceutical companies, as the spread of the uncommon Corona epidemic was a profitable deal for these companies that worked to develop vaccines against it, which proved effective beyond expectations, to tweet their shares in the sky With impressive gains, albeit the emergence of a new strain of the virus was somewhat irritable.
and of the 168 possible vaccines against Corona, according to the World Health Organization, the Pfizer, Biontech, and Modernac vaccines attracted the world's attention after they proved the effectiveness of about 95% to prevent the epidemic, so it is no wonder that the shares of these companies are the biggest winners Especially with the start of vaccination with these vaccines in several countries, led by the United States, and investors' optimism that distributing the vaccine on a larger scale will generate billions of dollars for these companies in the next year.
In general, the Nasdaq index of biotechnology companies achieved gains of more than 30% in 2020 and is still continuing its gains since the beginning of the year to trade above 5,000 points on the date of preparing this report as the following chart shows: -
and before the epidemic, little was known about our country, but now, after a few months, it has become a billionaire thanks to the development of the Corona vaccine, with its market value reaching 50 billion dollars, after the stock jumped by about 600% this year, Indicates investors betting on strong gains in the coming period.
And even before the modernization of our vaccine was distributed on a larger scale, and once it was determined to develop it, this reflected positively on the company's revenues in the third quarter, reaching 157.9 million dollars, a wide difference from the comparative period of last year at 17 1 million, thanks to the funding it received from governments and charitable organizations to develop the Corona vaccine.Overall, governments gave 6.5 billion pounds to vaccine-developing companies, according to scientific data analytics company Irventy, and non-profit organizations gave them nearly 1.5 billion pounds / p>
At this point, we must note that companies usually do not resort to private financing except in the event that they deal with a virus that is expected to continue for years and the world coexists with, and this is what made the majority of companies developing vaccines obtain funding from the government At the beginning, but with the uncertainty surrounding the date of the end of the Corona virus, such companies have added private financing, as they bet that they will produce additional doses and achieve profits in the long term and hope will not stop, as happened in previous viruses such as SARS.
Moderna is considered among the companies that aim to achieve profits for shareholders, as its vaccine, whose dose reaches $ 37, is the highest among the companies developing the Corona vaccine, in contrast to Astrazhnica, which said that it will price its vaccine to reach $ 8.1, which is The lowest price at which the company can cover costs only, and this may be behind the stock's abandonment of its highest levels and turning into losses by about 4% in 2020.
Moderna investors expect the company to generate between 10 and 15 billion dollars from the sale of its vaccine in 2021 and 2022, and several million more in the following years, according to estimates by Morgan Stanley, and these numbers are especially staggering when you consider that ...
